Prof. Bryan Morton CBE
Bryan has over 30 years’ experience as a successful entrepreneur and senior manager in the pharmaceutical industry. He founded EUSA Pharma, Inc. in 2006 and most recently served as its President and Chief Executive Officer until it was sold to Jazz Pharmaceuticals in June 2012 for $700m. prior to its sale. He has significant international experience, having worked extensively in the USA, Australia and Belgium, in addition the UK, and has a rich knowledge of pharmaceuticals and medical devices, which he brings to Izana.
He began his pharmaceutical career in sales and has held positions in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry largely with Merck and Co. Inc. and Bristol Myers Squibb.
Dr. Someit Sidhu
Someit Sidhu is CEO and Co-founder of Izana Bioscience.
Someit is a graduate from the Oxford Medical School and after spending time working in Cardiology and General Surgery he became a management consultant at McKinsey & Co.
During his time at McKinsey he focused on Pharmaceutical R&D and Portfolio Strategy, serving many large international pharmaceutical companies.
Dr. Tim Corn
Chief Medical Officer
Tim Corn is Chief Medical Officer of Izana Bioscience.
Tim was formerly Senior Vice President, Clinical Development at Jazz Pharmaceuticals. Before this he was Chief Medical Officer at EUSA Pharma, Inc. which was established in 2006 and acquired by Jazz Pharmaceuticals in 2012. Prior to this he was CMO at Zeneus Pharma, which was acquired by Cephalon Inc. Dr Corn also serves as Chair of the Board of Trustees of The Neuro Foundation, as Non-Executive Director on the Boards of Reneuron plc, HRA Pharma and Neurocentrx Pharma Ltd, and as Chair of the Scientific Advisory Board of Autifony Therapeutics.
Dr. Corn qualified in medicine at King's College Hospital, London after gaining a Master’s degree in biochemistry from Imperial College. He became honorary consultant and senior lecturer in neuropsychiatry at the Institute of Psychiatry, London, and is the author of more than forty scientific publications. Dr Corn has held senior clinical and regulatory positions at GlaxoWellcome, MSD Research Laboratories, Athena Neuroscience and Elan as well as in the UK regulatory agency. He has played a key role in more than twenty regulatory approvals in the USA and Europe, the most recent of which were the approval by FDA of Erwinaze™ in acute lymphoblastic leukaemia and Defitelio in hepatic veno-occlusive disease in HSCT. He was elected Fellow of the Faculty of Pharmaceutical Medicine in 1996 and Fellow of the Royal College of Psychiatrists in 1998.
Send us an email using the form and one of the team will be in touch with you soon.